<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="99344"><DrugName>Ad26-RSV-FA2</DrugName><DrugSynonyms><Name><Value>Ad26-RSV-FA2</Value></Name><Name><Value>JNJ-61187165-AAA</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>human adenovirus-vectored vaccine (respiratory syncytial virus infection),Janssen Vaccines &amp; Prevention BV)</Value></Name></DrugSynonyms><CompanyOriginator id="28808">Janssen Vaccines &amp; Prevention BV</CompanyOriginator><CompaniesPrimary><Company id="28808">Janssen Vaccines &amp; Prevention BV</Company></CompaniesPrimary><CrossReferences><SourceEntity id="28808" type="Company"><TargetEntity id="4298547630" type="organizationId">Janssen Vaccines &amp; Prevention BV</TargetEntity></SourceEntity><SourceEntity id="287" type="ciIndication"><TargetEntity id="10061603" type="MEDDRA"></TargetEntity><TargetEntity id="D018357" type="MeSH"></TargetEntity><TargetEntity id="-1462311917" type="omicsDisease"></TargetEntity><TargetEntity id="866" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="287">Respiratory syncytial virus infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="12370">Recombinant viral vector vaccine</Action><Action id="12378">Prophylactic vaccine</Action></ActionsSecondary><Technologies><Technology id="62">Virus recombinant</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2018-08-17T10:58:28.000Z</LastModificationDate><ChangeDateLast>2018-08-17T00:00:00.000Z</ChangeDateLast><AddedDate>2015-10-06T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28808" linkType="Company"&gt;Janssen Vaccines &amp;amp; Prevention&lt;/ulink&gt;  (formerly Crucell Holland) is developing Ad26.RSV.FA2 (JNJ-61187165-AAA), monovalent, recombinant, replication-incompetent human adenovirus serotype 26-vectored vaccine encoding the pre-fusion conformation-stabilised F protein derived from the RSV A2 strain a prime-boost human, for the potential im prevention of respiratory syncytial virus infection. In October 2015, a phase I study began in the US [&lt;ulink linkID="1700026" linkType="Reference"&gt;1700026&lt;/ulink&gt;],  [&lt;ulink linkID="1700027" linkType="Reference"&gt;1700027&lt;/ulink&gt;], [&lt;ulink linkID="2062871" linkType="Reference"&gt;2062871&lt;/ulink&gt;]. In September 2016, the phase I trial was completed [&lt;ulink linkID="1700027" linkType="Reference"&gt;1700027&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2015, a phase I randomized, parallel assignment, double blind study (&lt;ulink linkID="241514" linkType="Protocol"&gt;NCT02561871&lt;/ulink&gt;; CR107705, VAC18192RSV1003) to assess the safety and tolerability of intramuscular prime-boost regimens of Ad26.RSV.FA2 given either once or twice followed by &lt;ulink linkID="97043" linkType="Drug"&gt;Ad35-RSV-FA2&lt;/ulink&gt; was to begin in the US in healthy adults (expected n = 34); at that time, the study was  completed in September 2016 [&lt;ulink linkID="1700026" linkType="Reference"&gt;1700026&lt;/ulink&gt;]. In October 2015,  the trial was initiated in the US [&lt;ulink linkID="1700026" linkType="Reference"&gt;1700026&lt;/ulink&gt;], [&lt;ulink linkID="1700027" linkType="Reference"&gt;1700027&lt;/ulink&gt;].  In September 2016, the phase I trial was completed [&lt;ulink linkID="1700027" linkType="Reference"&gt;1700027&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2018, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) [&lt;ulink linkID="2062871" linkType="Reference"&gt;2062871&lt;/ulink&gt;]&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28808">Janssen Vaccines &amp; Prevention BV</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-07T00:00:00.000Z</StatusDate><Source id="1700027" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28808">Janssen Vaccines &amp; Prevention BV</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="287">Respiratory syncytial virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-08-21T00:00:00.000Z</StatusDate><Source id="1700027" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="28808">Janssen Vaccines &amp; Prevention BV</OwnerCompany><Country id="EU">EU</Country><Indication id="287">Respiratory syncytial virus infection</Indication><AwardedIndication>Prevention of lower respiratory tract disease caused by respiratory syncytial virus</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-27T00:00:00.000Z</MileStoneDate><Source id="2062871" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="3814464" number="WO-2017174564" title="Vaccine against RSV"></PatentFamily><PatentFamily id="3814465" number="WO-2017174568" title="Stabilized soluble pre-fusion RSV F proteins"></PatentFamily><PatentFamily id="4495569" number="WO-2019086450" title="Adenovirus and uses thereof"></PatentFamily><PatentFamily id="4495571" number="WO-2019086456" title="Adenovirus and uses thereof"></PatentFamily><PatentFamily id="4495574" number="WO-2019086461" title="Adenovirus vectors and uses thereof"></PatentFamily><PatentFamily id="4495576" number="WO-2019086466" title="Adenovirus and uses thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pennsylvania" id="20658"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>